This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
EpimAb/Innovent FIT-Ig Bispecific Antibody Program
Innovent Biologics, Inc.
Drug Names(s): Fabs-In-Tandem Immunoglobulin Bispecific Antibody Program
Description: EpimAb and Innovent are developing bispecific antibodies using EpimAb’s proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform.
EpimAb and Innovent
In June 2016, EpimAb Biotherapeutics and Innovent Biologics announced a multiple target agreement for the development of bispecific antibodies. Under the terms of the agreement, Innovent will gain access to EpimAbs proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform to develop multiple bispecific antibodies for the Chinese market, including the right to out-license the developed programs outside of China. In return for commercialization rights to these molecules in China, EpimAb is eligible to receive an upfront payment and total milestones of up to $120 MM, plus royalties. In the event Innovent licenses the rights of the developed candidates outside of China, EpimAb will receive an undisclosed share of the net receipts. Further details of the terms were not disclosed.
Partners: EpimAb Biotherapeutics
EpimAb/Innovent FIT-Ig Bispecific Antibody Program News
Additional information available to subscribers only: